Negative impact of HIV infection on broad-spectrum anti-HCV neutralizing antibody titers in HCV-infected patients with advanced HCV-related cirrhosis - 27/05/22
, Isidoro Martínez a, b, ⁎ Abstract |
Objectives |
The current study aimed to assess the impact of HIV on the production of anti-HCV antibodies in HCV-infected individuals with advanced HCV-related cirrhosis before and 36 weeks after the sustained virological response (SVR) induced by direct-acting antivirals (DAAs) therapy.
Methods |
Prospective study on 62 patients (50 HIV/HCV-coinfected and 12 HCV-monoinfected). Plasma anti-E2 and HCV-nAbs were determined respectively by ELISA and microneutralization assays.
Results |
At baseline, the HCV-group had higher anti-E2 levels against Gt1a (p = 0.012), Gt1b (p = 0.023), and Gt4a (p = 0.005) than the HIV/HCV-group. After SVR, anti-E2 titers against Gt1a (p < 0.001), Gt1b (p = 0.001), and Gt4a (p = 0.042) were also higher in the HCV-group than HIV/HCV-group. At 36 weeks post-SVR, plasma anti-E2 titers decreased between 1.3 and 1.9-fold in the HIV/HCV-group (p < 0.001) and between 1.5 and 1.8-fold in the HCV-group (p ≤ 0.001). At baseline, the HCV-group had higher titers of HCV-nAbs against Gt1a (p = 0.022), Gt1b (p = 0.002), Gt2a (p < 0.001), and Gt4a (p < 0.001) than the HIV/HCV-group. After SVR, HCV-nAbs titers against Gt1a (p = 0.014), Gt1b (p < 0.001), Gt2a (p = 0.002), and Gt4a (p = 0.004) were also higher in the HCV-group. At 36 weeks post-SVR, HCV-nAbs decreased between 2.6 and 4.1-fold in the HIV/HCV-group (p < 0.001) and between 1.9 and 4.0-fold in the HCV-group (p ≤ 0.001).
Conclusions |
HIV/HCV-coinfected patients produced lower levels of broad-spectrum anti-HCV antibodies than HCV-monoinfected patients.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Neutralizing antibodies (HCV-nAbs) contribute to protection against HCV infection. |
• | HIV/HCV patients had lower anti-E2 antibodies and HCV-nAbs titers than HCV patients. |
• | Plasma titers of anti-E2 antibodies and HCV-nAbs decrease after SVR with DAAs. |
List of abbreviations : AUC, CTP, DAAs, DMEM, ELISA, FBS, HCV, HCVcc, HCV-nAbs, HIV, HVPG, IFN, IQR, LSM, MSM, PWID, SPSS, SVR
Keywords : Hepatitis C, HIV, HIV/HCV coinfection, Broad-spectrum neutralizing antibodies, Direct-acting antivirals, HCV clearance
Plan
Vol 150
Article 113024- juin 2022 Retour au numéro
Article précédent
- Hydrogen sulfide ameliorated preeclampsia via suppression of toll-like receptor 4-activated inflammation in the rostral ventrolateral medulla of rats
- Jiexian Du, Ping Wang, Qi Gou, Sheng Jin, Hongmei Xue, Desi Li, Danyang Tian, Jianping Sun, Xiangjian Zhang, Xu Teng, Yuming Wu
- Evaluation of protective effects of methylene blue on cisplatin-induced nephrotoxicity
- Obaidullah Usefzay, Siamak Yari, Parsa Amiri, Parisa Hasanein
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?